Today, DSM Deretil, global leader in the field of development, production and sales of side chains for betalactamic antibiotics and the Chinese company Shangyu Yuntao Chemicals, announced that they have formed a Joint Venture for the production of DL Phenyl Glycine and D(-) Phenyl Glycine. DSM Deretil acquired 51% of the shares and obtained an option to acquire the remaining 49% to gain full ownership of the company within the next three years.

“With this joint venture we realize the opportunity to combine Deretil’s superior technology with the low cost infrastructure of a Chinese manufacturer. This enables us to further build on the value proposals we can make to our customers and supply them with the quality they need in the highly competitive anti-infectives market”, concludes Lluis Franquesa, General Manager of DSM Deretil at the closing of the agreement.

“ China plays a key role in the production of antibiotics”, comments Lluis Franquesa, “The joint venture of DSM Deretil and Shangyu Yuntao Chemicals in China highlights DSM’s strong commitment to continue to play its leading role in this business.”

About DSM Deretil
DSM Deretil is part of DSM N.V. through its DSM Anti-Infectives Business Group and is the worldwide leading company in the field of development, production and sales of side chains for betalactamic antibiotics, the largest group of pharmaceuticals to combat diseases based in bacterial infections. DSM Deretil employs 300 people in its plant in Almeria and offices in Barcelona, both in Spain.